Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Myocardial infarction diagnosis IVD gene and application thereof

A myocardial infarction and gene technology, which is applied in disease diagnosis, microbial determination/examination, biochemical equipment and methods, etc., can solve the problem of unclear expression of related genes, and achieve timely gene diagnosis, more gene diagnosis, and lower reduction. effect on mortality

Inactive Publication Date: 2018-11-06
BEIJING MEDINTELL BIOMED CO LTD
View PDF11 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A variety of physiological processes accompany the occurrence of myocardial infarction, such as inflammation, abnormal calcium uptake, cell cycle abnormalities, peptide secretion, oxidative stress, apoptosis, etc., and the precise timing of these processes and the occurrence of myocardial ischemia are currently unknown. When some related genes are expressed is not clear and needs to be further explored

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Myocardial infarction diagnosis IVD gene and application thereof
  • Myocardial infarction diagnosis IVD gene and application thereof
  • Myocardial infarction diagnosis IVD gene and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 Screening of genes differentially expressed in patients with myocardial infarction and normal people

[0035] 1. Research object

[0036] Select 6 hospitalized patients with myocardial infarction treated in the hospital as research objects, including 3 males and 3 females, with an average age of 56.00±8.75; 7 healthy people in the control group; each of the above-mentioned patients and healthy people who were invited to participate in the study All signed the informed consent.

[0037] 2. Sample collection and storage

[0038] On the day of admission, 8 mL of fresh sterile arterial blood was collected into EDTA anticoagulated purple tubes before coronary angiography. If it is not used immediately, the sample can be stored in a refrigerator at 4°C for 2 hours.

[0039] 3. Separation of PBMCs by Ficoll method

[0040] The following steps are all completed in the ultra-clean bench:

[0041] (1) Dilute the blood sample with equal volume of normal saline, add ...

Embodiment 2

[0063] Embodiment 2QPCR experiment verifies the genes differentially expressed in patients with myocardial infarction and normal people

[0064] 1. Research object:

[0065] The screening criteria were the same as in Example 1, 35 patients with myocardial infarction and 35 normal subjects.

[0066] 2. Extraction of total RNA in blood

[0067] Step is with embodiment 1.

[0068] 3. RT-PCR

[0069] (1)RT

[0070] RT reaction system (20μl):

[0071]

[0072] RT reaction procedure:

[0073] 42°C 15min

[0074] 85℃ 5s

[0075] 4℃ ---

[0076] (2) qPCR

[0077] PCR reaction system (20μl):

[0078]

[0079] PCR reaction program:

[0080] Amplification procedure:

[0081] Stage 1 95°C 10min

[0082] Stage 2 95°C 10s

[0083] 57°C 10s

[0084] Repeat for 42 cycles

[0085] Three replicate wells were set for each sample, and the internal reference was GAPDH.

[0086] (3) Primers

[0087] The primer sequences of IVD gene and GAPDH gene are as follows:

[0088] GAPD...

Embodiment 3

[0101] Example 3 Western blot experiment to verify the expression products of differentially expressed genes in patients with myocardial infarction and normal people

[0102] 1. Research object: same as embodiment 2.

[0103] 2. Mononuclear cell isolation

[0104] Take 10ml of venous blood from patients with myocardial infarction and normal people, inject it into a sterile vial containing heparin, and shake it gently immediately after capping. Add an equal volume of HBSS (NaCl 8.0g, NaCl 2 HPO 4 0.132g, KH 2 PO 4 0.06g, KCl0.4g, phenol red 1ml, NaHCO 3 0.35g, D-glucose 1.0g, dissolved in 1000ml double distilled water), to reduce the aggregation of red blood cells. Draw 8ml of lymphocyte stratification solution into a 50ml centrifuge tube, slowly add the diluted blood along the tube wall, keep the interface clear, do not mix the two, centrifuge at 20°C 2000r / min for 30min, carefully absorb the stratification solution and plasma transfer The turbid off-white layer, tha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a molecular marker for the diagnosis of myocardial infarction. The molecular marker is IVD. By detecting the levels of an IVD gene and an IVD protein in the blood of a subject,whether the subject suffers from myocardial infarction or has the risk of suffering from the myocardial infarction is judged. A product for diagnosing the myocardial infarction through the content ofthe IVD gene or the IVD protein is developed according to the IVD gene and the IVD protein, and the diagnosis product can be popularized and used clinically.

Description

technical field [0001] The invention belongs to the field of molecular diagnosis, and relates to an IVD gene for diagnosing myocardial infarction and its application. Background technique [0002] Myocardial infarction is a global public health problem that seriously threatens public health (J.Ross, Jr., A50-year research journey. From laboratory to clinic, Circulation journal: official journal of the Japanese Circulation Society, 73(2009 ) 3-12; D. Lloyd-Jones, R. Adams, M. Carnethon, G. De Simone, T. B. Ferguson, K. Flegal, E. Ford, K. Furie, A. Go, K. Greenlund, N. Haase , S. Hailpern, M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M. McDermott, J. Meigs, D. Mozaffarian, G. Nichol, C . O'Donnell, V. Roger, W. Rosamond, R. Sacco, P Sorlie, R. Stafford, J. Steinberger, T. Thom, S. Wasserthiel-Smoller, N. Wong, J. Wylie-Rosett, Y. Hong, C. American Heart Association Statistics, S.). Several methodologies can be effectively applied to the t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6883G01N33/68
CPCC12Q1/6883G01N33/68G01N2800/324
Inventor 李曙光靳传娣
Owner BEIJING MEDINTELL BIOMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com